Cambridge Healthtech Instituteの第2回年次
Emerging Immune Modulation Strategies
Pre-Conference Symposium Registration Open and Morning Coffee8:00 am
PROFILING IMMUNE MICROENVIRONMENTS
High-Resolution Mapping of Tumor Cell, Immune Cell, and Immune Synapse Protein Microenvironments
Rob Oslund, PhD, Vice President, Platform Technologies, InduPro, Inc.
Membrane proteins play essential roles in driving intra- and inter-cellular function that are heavily influenced by the surrounding protein microenvironments they inherently experience. This inherent protein proximity is not only crucial for impacting how proteins function but also informs our ability to effectively target/modulate cell surface environments for therapeutic benefit. This talk will describe the development of a novel light-mediated catalytic microenvironment labeling toolbox for identifying proximal protein environments within intra and intercellular regions as well as downstream applications of the technology.
Identification of Antigen-Specific T Cells via FucoID for Cancer Immunotherapy
Peng Wu, PhD, Professor, Chemical Physiology, Scripps Research Institute
Reactivation and clonal expansion of tumor-specific antigen (TSA)-reactive T cells are critical for the success of checkpoint blockade and adoptive transfer of tumor-infiltrating lymphocytes (TIL)-based therapies. There are no reliable markers to specifically identify the repertoire of TSA-reactive T cells due to their heterogeneous composition. In this presentation, I will introduce FucoID as a genetic engineering-free method for the detection and isolation of TSA-reactive T cells. With its rapid turnover cycle, FucoID has the potential to accelerate the pace of personalized cancer therapy.
Sponsored Presentation (Opportunity Available)10:00 am
Networking Coffee Break10:15 am
Analysis Platforms to Quantify Tumor-Immune Interactions through Multiplexed Spatial Profiling Technologies
Arvind Rao, PhD, Associate Professor, Department of Computational Medicine and Bioinformatics, University of Michigan
Spatial profiling technologies like hyper-plex immunostaining in tissue, spatial transcriptomics have the potential to enable a multi-factorial, multi-modal characterization of the tissue microenvironment. Objective scoring methods inspired by recent advances in statistics and machine learning can serve to aid the interpretation of these datasets, as well as their integration with other, companion data like genomics. In this talk, we will discuss elements of spatial profiling from multiple studies as well as paradigms from statistics and machine learning in the context of these problems.
Next-Generation Tools for Spatial Genomics
Fei Chen, PhD, Assistant Professor, Stem Cell & Regenerative Biology, Broad Institute
Here, we’ll describe a new technology called Slide-tags in which single nuclei within an intact tissue section are "tagged" with spatial barcode oligonucleotides derived from DNA-barcoded beads with known positions. We adapted Slide-tags for T cell receptor sequencing to spatially map T cell clonality in single nuclei. We also implemented Slide-tags to quantify genetic alterations at single-nucleus spatial resolution by targeted sequencing of single-nucleotide variations captured in the transcriptome. Slide-tags offers a universal platform for importing established single cell measurements of gene expression, epigenetic regulation, and antibody-based quantification into the spatial genomics repertoire.
Enjoy Lunch on Your Own11:30 am
NOVEL IMMUNE TARGETING THERAPIES
Engineering Antigen-Specific Immune Tolerance with Glycosylated Amino Acids
Daniel Mandell, PhD, CEO & Co-Founder, GRO Biosciences, Inc.
Current approaches to treating autoimmune disease and attenuating immunogenicity of therapeutics broadly suppress the immune system. These approaches leave patients vulnerable to infection, cancer, and metabolic dysregulation. Further, such approaches only modify symptoms rather than treat underlying disease. Tolerizing patients to specific antigens is a holy-grail challenge that can displace systemic immunosuppression. GRObio’s ProGly approach to immunotolerization enables reversal of autoimmune disease and elimination of anti-drug antibodies without systemic immunosuppression.
Targeting Tissue Modalities to Increase Efficacy and Decrease Toxicities of Immune Modulators
Charlotte Moser, PhD, MD, MBA, CMO, Deka Biosciences
Cytokines are very potent and can steer many related unwanted effects. By concentrating treatment directly in the tumor environment, the safety profile significantly improves, and cytokines can change this micro-environment by getting efficient activation of tumor cell destruction. Deka has designed novel immunotherapies targeted to the tumor environment using known receptors like EGFR, HER2, and VEGFR. Labelling studies are illustrative for targeted dosing and better drug distribution and kinetics.
Synthetic Transcription-Factor Activity Responsive (STAR) Gene Circuits for Cancer Immunotherapy
Ming-Ru Wu, MD, PhD, Assistant Professor, Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Harvard Medical School
We have developed synthetic cancer-targeting gene circuits that specifically target cancer cells. Once the circuits enter cells, they will sense the activity of several cancer-associated transcription factors and get activated in tumor cells to trigger tumor-localized combinatorial immunotherapy. Circuits mediate robust therapeutic efficacy in ovarian cancer mouse models. This platform can be adjusted to treat multiple cancer types and can potentially trigger genetically encodable immunomodulators as therapeutic outputs.
Sponsored Presentation (Opportunity Available)2:30 pm
Networking Coffee Break2:45 pm
Enhancing Bispecific Antibodies with Engineered Donor T Cells
Edo Kapetanovic, MD, PhD, Postdoctoral Scientist, Synthetic and Systems Immunology, ETH Zurich
Bispecific antibodies (bsAbs) used in cancer treatments require functional T cells; however, in patients, T cells are often damaged and depleted. Allogeneic T cells from healthy donors could enhance bsAb treatment, but they carry a high risk of GvHD. To address this, we developed Allogeneic-Engineered-Decoupled (AED) T cells. AED T cells can be activated via bsAb, but do not respond to host antigens, eliminating the risk of GvHD. This combination approach of healthy and safe donor T cells with bsAbs could lead to development of new and more effective cancer therapies.
The Future of Engineered Immune Cell Therapies
Close of Symposium4:00 pm
Dinner Short Course Registration*4:00 pm
*Premium Pricing or separate registration required. See Short Courses page for details.
Close of Day7:30 pm